


ADVANCE TRANSLATIONAL RESEARCH BY QUANTIFYING PROTEIN FUNCTIONS IN TISSUE WITH QF-PRO®

Elena Castellano¹, Cristina Cacho-Navas¹, Juan Gumuzio¹, James Miles¹, Fernando Aguirre¹, Peter J Parker^{1,2,3}, Veronique Calleja¹


¹HAWK Biosystems, Astondo Bidea 612, Science and Technology Park of Bizkaia, Spain; ²School of Cancer and Pharmaceutical Sciences, Kings College London, United Kingdom; ³Francis Crick Institute, 1 Midland Road, London, United Kingdom.

Overcoming the lack of predictive biomarkers with QF-Pro®


PD-1/PD-L1 interaction state is highly predictive of immunotherapy response



- QF-Pro® is an enhanced FRET-FLIM-based technology.
- Compatible with current FFPE samples established workflow.
- Proven to determine clinical cut-off value for stratifying patients for treatment.



QF-Pro® highly predicts response to immunotherapy



Clinical cut-off
2.127%


Immune checkpoint pathways lack efficient predictive biomarkers:

- Low-response rates due to a lack of robust predictive biomarkers.
- The current gold-standard (PD-L1 TPS) fails to stratify patients for treatment.
- Unsustainable burden on patients and healthcare systems.

QF-Pro® predicts patient response to anti-PD-1/PD-L1 therapies

- QF-Pro® identifies PD-1/PD-L1 interaction as a predictive biomarker.
- QF-Pro® effectively stratifies NSCLC patients to receive immune checkpoint inhibitors therapies.
- QF-Pro® spatially quantifies the functional states of proteins.

Beyond PD-1/PD-L1: QF-Pro® empowers your research to discover new biomarkers with unmatched precision and efficiency.



QF-Pro®

- Quantitative and versatile platform.
- Compatible with all FFPE samples and fixed cells.
- Multiplex technique for developing novel biomarker profiles.
- Groundbreaking Companion Diagnostics.

